MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$9,043K
Net Income
-$89,535K
Net Profit Margin
-990.10%
EPS
-$0.81
Unit: Thousand (K) dollars
Revenue Breakdown
Collaboration Revenue
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-05-31
2026-02-28
2025-11-30
2025-08-31
Total revenue
9,043
6,252
6,055*
7,894
Research and development
87,653
84,137
70,579*
86,120
General and administrative
15,594
14,610
11,582*
13,159
Total operating expenses
103,247
98,747
82,160*
99,279
Loss from operations
-94,204
-92,495
-76,105*
-91,385
Interest and other income, net
4,398
5,321
6,096*
4,964
Loss before income taxes
-89,806
-
-70,009*
-86,421
Provision for (benefit from) income taxes
-271
-
-380*
0
Net loss
-89,535
-87,174
-69,629
-86,421
Basic EPS
-0.81
-0.79
-0.757
-1.03
Diluted EPS
-0.81
-0.79
-0.757
-1.03
Basic Average Shares
111,084,423
110,071,668
91,958,908
84,159,336
Diluted Average Shares
111,084,423
110,071,668
91,958,908
84,159,336
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$89,535K
(-106.00%↓ Y/Y)
Provision for (benefit
from) income taxes
-$271K
(-135.66%↓ Y/Y)
Loss before income
taxes
-$89,806K
(-110.30%↓ Y/Y)
Interest and other
income, net
$4,398K
(-21.72%↓ Y/Y)
Collaboration Revenue
$9,043K
(-35.66%↓ Y/Y)
Loss from operations
-$94,204K
(-94.95%↓ Y/Y)
Total revenue
$9,043K
(-79.47%↓ Y/Y)
Total operating
expenses
$103,247K
(11.77%↑ Y/Y)
Research and development
$87,653K
(12.24%↑ Y/Y)
General and
administrative
$15,594K
(9.19%↑ Y/Y)
Buy us a coffee
Nurix Therapeutics, Inc. (NRIX)
Nurix Therapeutics, Inc. (NRIX)